Theravance Biopharma
TBPH
TBPH
135 hedge funds and large institutions have $512M invested in Theravance Biopharma in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 54 increasing their positions, 32 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
3% more funds holding
Funds holding: 131 → 135 (+4)
2.12% more ownership
Funds ownership: 90.75% → 92.87% (+2.1%)
99% less call options, than puts
Call options by funds: $3K | Put options by funds: $286K
Holders
135
Holding in Top 10
5
Calls
$3K
Puts
$286K
Top Buyers
| 1 | +$7.59M | |
| 2 | +$5.53M | |
| 3 | +$2.82M | |
| 4 |
NM
Newtyn Management
New York
|
+$2.12M |
| 5 |
Morgan Stanley
New York
|
+$1.83M |
Top Sellers
| 1 | -$6.07M | |
| 2 | -$2.81M | |
| 3 | -$2.73M | |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$1.98M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.56M |
